Person: KORTEN, VOLKAN
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
KORTEN
First Name
VOLKAN
Name
16 results
Search Results
Now showing 1 - 10 of 16
Publication Metadata only Susceptibility of bacterial isolates from Turkey - A report from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program(TAYLOR & FRANCIS LTD, 2007) KORTEN, VOLKAN; Eraksoy, H.; Basustaoglu, A.; Korten, V.; Kurt, H.; Ozturk, R.; Ulusoy, S.; Yaman, A.; Yuce, A.; Zarakolu, P.The study monitored the susceptibility of nosocomial pathogens to meropenem and comparator antimicrobial agents isolated as part of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program from Turkish university hospitals. In terms of minimum inhibitory concentration 90% (MIC90) values, meropenem was two- and eight-fold more active than imipenem against Escherichia coli and Klebsiella pneumoniae, respectively. 40.5% of K. pneumoniae, 23.1% of Klebsiella oxytoca and 15.3% of E. coli isolates were extended-spectrum P-lactamase (ESBL) producers. Piperacillin/tazobactam was the most active agent against isolates of Pseudomonas aeruginosa, followed by meropenem and imipenem. Against Acinetobacter baumannii isolates, meropenem and imipenem were the most active agents. Continued surveillance by the MYSTIC Program appears to be prudent to help focus on effective empiric treatment regimens.Publication Open Access Crimean-Congo Hemorrhagic Fever in Turkey(2004-08) KORTEN, VOLKAN; Karti, S. Sami; Odabasi, Zekaver; Korten, Volkan; Yilmaz, Mustafa; Sonmez, Mehmet; Caylan, Rahmet; Akdogan, Elif; Eren, Necmi; Koksal, Iftihar; Ovali, Ercument; Erickson, Bobbie R.; Vincent, Martin J.; Nichol, Stuart T.; Comer, James A.; Rollin, Pierre E.; Ksiazek, Thomas G.Publication Metadata only 11th European Congress on Clinical Microbiology and Infectious Diseases - Istanbul, Turkey, 2 April 2001 - Introduction(W B SAUNDERS CO LTD, 2002) KORTEN, VOLKAN; Finch, R; Korten, VPublication Open Access Vancomycin versus Placebo for Treating Persistent Fever in Patients with Neutropenic Cancer Receiving Piperacillin-Tazobactam Monotherapy(2003-08-01) KORTEN, VOLKAN; Cometta, A.; Kern, W. V.; De Bock, R.; Paesmans, M.; Vandenbergh, M.; Crokaert, F.; Engelhard, D.; Marchetti, O.; Akan, H.; Skoutelis, A.; Korten, V.; Vandercam, M.; Gaya, H.; Padmos, A.; Klastersky, J.; Zinner, S.; Glauser, M. P.; Calandra, T.; Viscoli, C.; The International Antimicrobial Therapy Group of the European Organization for Research Treatment of CancerPublication Metadata only Antibiotic resistance surveillance over a 4-year period (2000-2003) in Turkey: results of the MYSTIC Program(ELSEVIER SCIENCE INC, 2007) KORTEN, VOLKAN; Korten, Volkan; Ulusoy, Sercan; Zarakolu, Pinar; Mete, BirgulThe Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program is a global study that provides antimicrobial susceptibility data in centers prescribing meropenem. The activity of meropenem and 7 broad-spectrum antimicrobials have been examined against 5208 bacterial isolates from 9 Turkish centers between 2000 and 2003. Cumulative susceptibility rates against all species of Enterobacteriaceae combined were ranked as follows: meropenem (99.3%), imipenem (97.6%), cefepime (80.0%), piperacillin-tazobactam (73.6%), ceftazidime (70.3%), ciprofloxacin (70.1%), cefotaxime (66.9%), and tobramycin (67.2%). The production of extended-spectrum beta-lactamases (ESBLs) was detected in 48.7% of Klebsiella pneumoniae and in 19.5% of Escherichia coli isolates. Of ESBL producing K. pneumoniae isolates, 75.7% were resistant to tobramycin, 40.3% to ciprofloxacin, and 48.3% to piperacillin-tazobactam. Only piperacillin/ tazobactam and carbapenems were active against more than 50% of Pseudomonas aeruginosa at the National Committee for Clinical Laboratory Standards-susceptible breakpoint, and the carbapenems were the most active compounds against Acinetobacter spp. These data confirm the continued potency of meropenem against Enterobacteriaceae in units where it is actively being prescribed. (c) 2007 Elsevier Inc. All rights reserved.Publication Open Access An unusual native tricuspid valve endocarditis caused by Candida colliculosa(BLACKWELL PUBLISHING LTD, 2003-04) DURMUŞOĞLU, LÜTFİYE; Kaygusuz, I; Mulazimoglu, L; Cerikcioglu, N; Toprak, A; Oktay, A; Korten, VCandida colliculosa , which grew in blood cultures of a 71-year-old retired man with fever of unknown origin that had lasted for 7 months, in conjunction with transthoracic echocardiography, demonstrating a 20-mm vegetation, superior to the tricuspid valve, herniating into the right atrial cavity. The finding led to the diagnosis of fungal endocarditis. Fluconazole, 600 mg daily, was commenced for 8 days; followed by amphotericin B, 1 mg/kg daily. On the fourth day of the amphotericin B treatment, the patient underwent replacement of the infected tricuspid valve. Even though the initial postoperative period was relatively uncomplicated, the patient died after a gross aspiration on the 67th day of his hospital stay, despite aggressive cardiovascular support and antimicrobial therapy. This is the first report of a native tricuspid valve fungal endocarditis due to C. colliculosa or Torulaspora delbrueckii , which is not known to be a human pathogen.Publication Metadata only Influence of oral glycopeptides on the fecal flora of human volunteers: Selection of highly glycopeptide-resistant enterococci(Oxford University Press, 1996) KORTEN, VOLKAN; Van Der Auwera P., Pensart N., Korten V., Murray B.E., Leclercq R.Changes in fecal flora were evaluated in 22 healthy volunteers administered oral vancomycin or teicoplanin in 1989-1991 in Belgium. Evaluation of 5 colonies per subject revealed no glycopeptide-resistant enterococci in the predominant flora before glycopeptide administration; however, large numbers (mostly Enterococcus faecium) emerged by the end of the study in 14 (64%) of the subjects. Pediococci and lactobacilli also increased in number. In 1992, 40 healthy volunteers and 33 cancer patients were evaluated by plating stool samples directly onto selective media containing vancomyein; low numbers of vancomycin-resistant enterococci (<50 cfu/g) were found in 11 (28%) of the 40 and 4 (12%) of the 33 samples, respectively. DNA restriction fragment length polymorphism analysis showed that most isolates were different, but all contained vanA in Tn1546-like elements. These results indicate that vanA and Tn1546-like elements were common in Belgium as early as 1989 and that community-based individuals in that location likely form a major reservoir for glycopeptide-resistant enterococci.Publication Open Access Increasing carbapenem resistance due to the clonal dissemination of oxacillinase (OXA-23 and OXA-58)-producing Acinetobacter baumannii: report from the Turkish SENTRY Program sites(MICROBIOLOGY SOC, 2008-12-01) KORTEN, VOLKAN; Gur, Deniz; Korten, Volken; Unal, Serhat; Deshpande, Lalitagauri M.; Castanheira, MarianaA significant increase in carbapenem-resistance rates among Acinetobacter baumannii isolates collected in two Turkish medical centres was detected in the 2000-2006 period (20-60%) by the SENTRY Antimicrobial Surveillance Program. Carbapenem-resistant strains from 2006 were evaluated for the presence of encoding genes and epidemic clonality. OXA-58-like and OXA-23-like carbapenemase-producing strains were detected in both medical institutions. Seventeen out of 18 strains from Ankara were positive for bla(OXA-58) primers and belonged to the same clone, whilst 26 isolates (25 from Istanbul and one from Ankara) harboured bla(OXA-23)-like genes and showed identical or similar PFGE patterns. Isolates producing OXA-23-like carbapenemases were more resistant than OXA-58-like carbapenemase producers to non-carbapenem antimicrobial agents. Carbapenem resistance in these institutions was observed to be largely driven by the dissemination of clones producing OXA-type carbapenemases.Publication Open Access Disseminated Flavimonas oryzihabitans Infection in a Diabetic Patient Who Presented with Suspected Multiple Splenic Abscesses(1997-08) HASDEMİR GÖKBOĞA, MÜNEVVER UFUK; Kirtş, Serhan; Över, Ufuk; Babacan, Funda; Lawrence, Roger; Korten, VolkanPublication Metadata only Subcutaneous nodules caused by Pseudomonas aeruginosa: healing without incision and drainage(1992) KORTEN, VOLKAN; Korten, V.; Gürbüz, O.; Firatli, T.; Bayik, M.; Akoglu, T.In a patient with multiple myeloma, numerous indurated, subcutaneous nodules and pyomyositis due to Pseudomonas aeruginosa were noted. These lesions resolved with ciprofloxacin plus ceftazidime therapy without surgical incision and drainage. Despite another course of cancer chemotherapy after total disappearance, there were no recurrences at the end of 3 months. Quinolones initially combined with other antipseudomonal beta-lactam agents may be the drugs of choice in the management of patients with subcutaneous nodules caused by P. aeruginosa.